P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 855-856
10.1097/01.hs9.0000846728.05693.f8